Sort
10,766 grants matching “checkpoint inhibitor”
An immune system biology approach to spatial and temporal mechanisms of cancer immunotherapy
$0Vivien Ileana Maltez · U.S. National Inst Allergy & Infect Dis · FI2 · FY2019 · GM
RadIO: A Novel Radiomics Toolkit to Predict and Characterize Response to Immunotherapy in Stage III Non-Small Cell Lung Cancer
$0Anant Madabhushi · Veterans Health Administration · I01 · FY2025 · VA
The long non-coding RNA LINC01133 as a novel determinant of immune evasion in triple-negative breast cancer
$0Antoine Elias Karnoub · Va Boston Health Care System · I01 · FY2025 · VA
DC-HIL in cancer
$0Ponciano D Cruz · Va North Texas Health Care System · I01 · FY2021 · VA
Role of Sphingolipids in KRAS induced lung adenocarcinoma
$0Mark Onaitis · Va San Diego Healthcare System · I01 · FY2025 · VA
Targeting lymphoid tissue residency to boost tumor immunotherapies
$0Nu Zhang · South Texas Veterans Health Care System · I01 · FY2024 · VA
The role of eosinophils and oxidative stress in esophageal malignancy
$0Yash Choksi · Veterans Health Administration · IK2 · FY2023 · VA
Targeting lymphoid tissue residency to boost tumor immunotherapies
$0Nu Zhang · South Texas Veterans Health Care System · I01 · FY2023 · VA
BLRD Merit Review Research Career Scientist (RCS) Award (IK6)
$0Jin Chen · Veterans Health Administration · IK6 · FY2023 · VA
Programming Durable Immune Responses in Lung Cancer
$0Sherven Sharma · Va Greater Los Angeles Healthcare System · I01 · FY2019 · VA
Melanoma Resistance to Apoptosis: Mechanisms and Therapeutic Potential
$0Yiqun G Shellman · Va Eastern Colorado Health Care System · I01 · FY2024 · VA
Combined inhibition of PLK1 and NOTCH for melanoma management
$0Nihal Ahmad · Wm S. Middleton Memorial Veterans Hosp · I01 · FY2023 · VA
DC-HIL in cancer
$0Ponciano D Cruz · Va North Texas Health Care System · I01 · FY2023 · VA
BLRD Research Career Scientist Award Application
$0Sushanta K Banerjee · Kansas City Va Medical Center · IK6 · FY2023 · VA
New Approaches to Combat CNS Inflammation: Targeting a Metabolic Enzyme in Demyelinating Disease
$0Brian A. Zabel · Veterans Admin Palo Alto Health Care Sys · I01 · FY2024 · VA
Autoinflammation in Human Melanoma
$0Mayumi Fujita · Va Eastern Colorado Health Care System · I01 · FY2019 · VA
Targeting mTORC2 in lung squamous cancer
$0Jin Chen · Veterans Health Administration · I01 · FY2024 · VA
Type I Interferon Regulation of PD-L1 Expression and Function in MDSCs
$0Kebin Liu · Charlie Norwood Va Medical Center · I01 · FY2021 · VA
Activation of immunosupressive oxidative stress response pathways by tobacco exposure in head and neck cancer
$0Vlad C Sandulache · Michael E Debakey Va Medical Center · I01 · FY2024 · VA
Regulation of cutaneous immune function and anti-tumor immune responses by PPARgamma-mediated transrepressive signaling
$0Raymond L Konger · Rlr Va Medical Center · I01 · FY2019 · VA
Targeting Integrins in Lung Cancer
$0Tianhong Li · Va Northern California Health Care Sys · I01 · FY2024 · VA
TELOMERASE ACTIVITY, TELOMERE FUNCTION, CHROMOSOME STABI
$0Johns Hopkins University · P01 · FY2000 · CA
Targeting mTORC2 in lung squamous cancer
$0Jin Chen · Veterans Health Administration · I01 · FY2023 · VA
BCCMA: Translational research to improve the care of advanced bladder cancer
$0Chong-Xian Pan · Va Boston Health Care System · I01 · FY2023 · VA
ANTIPROLIFERATIVE EFFECTS OF SMALL MOLECULES
$0Dental &Craniofacial Research · Z01 · FY2000 · DE